Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
India’s drug companies that come under essential services are handing out incentives and assurance of a sterile work environment to workers, to motivate them to get to work in the wake of the Covid-19 pandemic.
As the May 3 deadline for the lockdown nears, medical experts feel the next month can be "make or break" for the fight against COVID-19 and an aggressive containment strategy for hotspots along with insulation of green zones is essential while giving some relaxations.
The Supreme Court bench asked the plea filed by an NGO, 'People for Better Treatment' (PBT), to be considered as representation to the ICMR. During the hearing, Ohio-based Indian origin doctor and PBT President Kunal Saha said he has not challenged the treatment line for Covid-19 per se but the use of HCQ and AZM combination has side effects and people are dying due to it.
These directives will come into force from 10 am on May 2, 2020 as Maharashtra chief secretary took note of reports of hospitals turning away patients due to increasing number of Covid-19 patients.
Although the study is the first randomised controlled trial -- considered the gold standard for evaluating the effectiveness of interventions -- of remdesivir, the researchers cautioned that interpretation of their findings is limited because the study was stopped early after they were unable to recruit enough patients due to the steep decline in cases in China.
Glenmark Pharmaceuticals on Thursday said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.
Industry executives and chemists said the April sales data showed a month-on-month decline of 30-40%. But even though the lockdown is seen to be impacting sales of most drugs, the pattern for medicines for infections and flus is no different.
The main reason why it is always difficult to run a campaign for Universal Healthcare is because we fall sick singly and alone. When we are ill all we can think about is getting well. But when we are well, we don’t give illness a thought. An epidemic changes all that for illness now no longer strikes randomly and uniquely.
Many states are also administering the recommended concoctions and medicines to patients in government quarantine facilities with mild symptoms, those who are recovering from Covid-19 and also to their asymptomatic contacts.
"Our focus is ensuring that we are able to get approvals for all the necessary studies and data in India. We will be able to provide the drug once the Indian approvals come through. This is our main bottleneck now," said R Ananthanarayanan.
Hydroxychloroquine, besides being administered as an anti-malarial drug, is also used as a chronic therapy by patients suffering from auto immune diseases such as RA and Lupus. In the recent months the drug has been used in several countries including India and US in the treatment of critically ill Covid-19 patients.
The company has agreed to acquire stressed assets from Saraswat Cooperative Bank by way of cash consideration of Rs 61 crore subject to closing adjustments, Bajaj Healthcare said in a regulatory filing. The targeted assets have installed capacity of 111 metric tonnes per month and are capable of manufacturing bulk drugs and active pharmaceutical ingredients (API).
Fortis Healthcare on Wednesday said it has rolled out online consultations for patients in 23 hospitals across its country-wide network amid the lockdown to contain coronavirus infections.
Those working in the Central government will have to review their status on the Aarogya Setu app before they start for office and continue only when the app shows "safe" or "low risk" status. The effective use of the App will help break the chain of transmission of Covid-19, stated the notice.
Strides Pharma Science Ltd on Wednesday said it has developed and commercialised Favipiravir antiviral tablets and stressed that the drug has demonstrated positive outcomes in COVID-19 treatment globally.
Finding that India has a dearth of skilled technicians, the company has decided to increase the number of franchisees of its Enpidia Training Academy, which offers a diploma degree in dialysis with a focus on Hemodialysis. NephroPlus, which currently runs 11 institutions with 100 students each across India, plans to scale its intake by signing up another 14 franchisees.
AIIMS Director Dr Randeep Guleria said the mode of treatment in COVID-19 is still at an "experimental stage" and there is a need for good and well conducted research trials before its benefit and this mode of therapy can be recommended for routine use in coronavirus patients.
Lab technicians fighting the war against the coronavirus in India are armed with insufficient RNA extraction kits — one of the vital components needed for the test to confirm the infection.
Domestic manufacturers of rapid antibody rapid test kits for novel coronavirus have approached the Indian Council of Medical Research (ICMR) to provide known samples of Covid-19 positive patients and a dedicated testing body for quick validation of their pilot and manufactured batches.
More than a dozen importers continue to hold licences to buy coronavirus antibody test kits from two Chinese companies that the Indian Council of Medical Research (ICMR) has implicated for quality issues.
Hyderabad-based Natco Pharma Ltd on Tuesday said it has received the final approval from the US health regulator for its first supplemental abbreviated new drug application (sANDA) filed from its new drug formulations facility at Visakhapatnam, Andhra Pradesh.
"COVID-19 isn't going away anytime soon. Before we move into another lockdown, it is imperative that we have continued community monitoring especially in densely populated areas to serve as an early warning system," Catalyst Group Health Strategy Partner Angela Chaudhuri said in a statement.
Earlier, the samples from Ladakh had to be sent to Delhi by flights leading to delays and heavy expenditure. The COVID-19 testing laboratory, first such facility in the union territory, was set up with the help of Pernod Ricard India foundation. The new laboratory is a fully equipped facility compliant with Indian Council of Medical Research (ICMR) standards.
Struggling to scale up testing, India imported the antibody kits from China. The first set arrived last week and was dispatched to various states. However, several countries reported problems with the kits, although China denied there were any quality issues. Expert teams were sent to eight states following complaints that the test kits had generated inaccurate results.
The formulation made of herbs tulsi (basil leaves), Dalchini (cinnamon bark ), Sunthi (dry ginger powder) and krishna marich (black pepper) will be manufactured and sold in generic name ‘Ayush Kwath' or ‘Ayush Kudineer' or ‘Ayush Joshanda', according to a letter written by the ministry to all the States/UTs and ASU drug manufacturers on April 24.
